A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00337090

Enrollment

1108

Registered

2006-06-15

Start date

Unknown

Completion date

2007-03-31

Last updated

2013-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Keywords

Over Active Bladder, Urinary incontinence, YM178, Symptomatic Over Active Bladder

Brief summary

The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

Interventions

DRUGYM178

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months

Exclusion criteria

* Pregnant and breastfeeding women * Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)

Countries

Belgium, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026